English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Typically, about 90% of drug candidates are N-containing, and an even higher amount are O-containing. As a consequence, it is not surprising that alkylation and arylation of groups with nitrogen and oxygen emerge as major reactions to obtain bioactive compounds.1 Xanthones are a class of O-heterocycles characterized by a dibenzo-γ-pyrone nucleus. This scaffold may be considered a “privileged structure” able of providing useful ligands for several types of receptors and/or enzymes targets by judicious structural modifications.2 In our search for potential anticancer drugs we pursuit with a hybridization approach of N-containing xanthones. N-Substitution is typically achieved by one of the following strategies: (i) direct reaction with alkyl-X or aryl-X, (ii) reductive alkylation using an appropriate aldehyde. Herein, exploiting chemical routes to reach for bioactive N-containing xanthones with will be shared. The synthesis of new xanthone derivatives proceeds by both strategies and the respective strengths and weakness will be presented in a “medchem” perspective. Although chemical route (i) (SN2 reactions and nucleophilic aromatic substitutions) provided interesting antitumor derivatives,3 the reductive amination (ii) furnished a library of potential p53:MDM2 inhibitors with noticeable advantages such as: high-yield reactions, one-pot conversions, aliphatic amines with low potential to form reactive metabolites. The use of a variety of (thio)xanthone building blocks, with various substituents, and different reaction conditions allowed us to develop a repertoire of N-transformations, often referred as the “chemist toolbox”.4  References   Carey, J. S.; Laffan, D.; Thomson, C.; Williams, M. T. Org. Biomol. Chem. 2006, 2337–2347.  Pinto, M. M. M.; Sousa, M. E.; Nascimento, M. S. J. Curr. Med. Chem. 2005, 12, 2517-2538.  Palmeira, A.; Vasconcelos, M. H.; Paiva, A.; Fernandes, M. X.; Pinto, M.; Sousa. E. Biochem. Pharmacol. 2012, 83, 57–68.  Roughley, S. D.; Jordan, A. M. J. Med. Chem. 2011, 54, 3451-3479.   Acknowledgments: This research was partially supported by ERDF through the COMPETE and national funds through FCT, under the project PEst-C/MAR/LA0015/2013.

Synthesis of Aminated Xanthones: Exploiting Chemical Routes to Reach for Bioactive Compounds